131
Views
29
CrossRef citations to date
0
Altmetric
Review

Secukinumab for rheumatology: development and its potential place in therapy

&
Pages 2069-2080 | Published online: 24 Jun 2016

References

  • ScottDLWolfeFHuizingaTWRheumatoid arthritisLancet201037697461094110820870100
  • McInnesIBSchettGThe pathogenesis of rheumatoid arthritisN Engl J Med2011365232205221922150039
  • KlareskogLAmaraKMalmströmVAdaptive immunity in rheumatoid arthritis: anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritisCurr Opin Rheumatol2014261727924257366
  • EderLChandranVPelletFHuman leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasisAnn Rheum Dis2012711505521900282
  • BrownMAKennaTWordsworthBPGenetics of ankylosing spondylitis–insights into pathogenesisNat Rev Rheumatol2016122819126439405
  • KaneDStaffordLBresnihanBFitzGeraldOA prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experienceRheumatology (Oxford)200342121460146814523223
  • van der HeijdeDBellamyNCalinADougadosMKhanMAvan der LindenSPreliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working GroupJ Rheumatol19972411222522299375888
  • ColebatchANMarksJLEdwardsCJSafety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)Cochrane Database Syst Rev201111CD00887222071858
  • van der HeijdeDBrebanMHalterDMaintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumabRheumatology (Oxford)20155471210121925541333
  • ScirèCACaporaliRSarzi-PuttiniPMonitornet projectDrug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet databaseClin Exp Rheumatol201331685786323981363
  • O’DellJRMikulsTRTaylorTHCSP 551 RACAT InvestigatorsTherapies for active rheumatoid arthritis after methotrexate failureN Engl J Med2013369430731823755969
  • SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
  • NamJLRamiroSGaujoux-VialaCEfficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritisAnn Rheum Dis201473351652824399231
  • KoendersMIvan den BergWBNovel therapeutic targets in rheumatoid arthritisTrends Pharmacol Sci201536418919525732812
  • SieperJPorter-BrownBThompsonLHarariODougadosMAssessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trialsAnn Rheum Dis20147319510023765873
  • SongIHHeldmannFRudwaleitMTreatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot studyAnn Rheum Dis20117061108111021415053
  • SongIHHeldmannFRudwaleitMOne-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flareAnn Rheum Dis201372230530622887847
  • Jimenez-BojEStammTASadlonovaMRituximab in psoriatic arthritis: an exploratory evaluationAnn Rheum Dis201271111868187122833373
  • MeasePGenoveseMCGladsteinGAbatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialArthritis Rheum201163493994821128258
  • McInnesIBKavanaughAGottliebABPSUMMIT 1 Study GroupEfficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialLancet2013382989478078923769296
  • GossecLSmolenJSRamiroSEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateAnn Rheum Dis201675349951026644232
  • Celgene CorporationStudy of Apremilast to Treat Subjects With Active Ankylosing Spondylitis (POSTURE) Available from: https://clinicaltrials.gov/ct2/show/NCT01583374
  • U.S. Food and Drug AdministrationFDA approves new psoriasis drug Cosentyx Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.htm
  • NovartisNovartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US Available from: https://www.novartis.com/news/media-releases/novartis-receives-two-new-fda-approvals-cosentyx-treat-patients-ankylosing
  • AggarwalSGurneyALIL-17: prototype member of an emerging cytokine familyJ Leukoc Biol20027111811781375
  • RouvierELucianiMFMattéiMGDenizotFGolsteinPCTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri geneJ Immunol199315012544554568390535
  • HarringtonLEHattonRDManganPRInterleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineagesNat Immunol20056111123113216200070
  • ParkHLiZYangXOA distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17Nat Immunol20056111133114116200068
  • GladiatorAWanglerNTrautwein-WeidnerKLeibundGut-LandmannSCutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infectionJ Immunol2013190252152523255360
  • FerrettiSBonneauODuboisGRJonesCETrifilieffAIL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible triggerJ Immunol200317042106211212574382
  • BucklandJNew role for mast cells as IL-17-expressing effector cells in established RANat Rev Rheumatol20106524320440895
  • SchwandnerRYamaguchiKCaoZRequirement of tumor necrosis factor receptor-associated factor (TRAF) 6 in interleukin 17 signal transductionJ Exp Med200019171233124010748240
  • GaffenSLStructure and signalling in the IL-17 receptor familyNat Rev Immunol20099855656719575028
  • MurphyCALangrishCLChenYDivergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammationJ Exp Med2003198121951195714662908
  • CuaDJSherlockJChenYInterleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature2003421692474474812610626
  • IvanovIIMcKenzieBSZhouLThe orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cellsCell200612661121113316990136
  • ManelNUnutmazDLittmanDRThe differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammatNat Immunol20089664164918454151
  • YePRodriguezFHKanalySRequirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defenseJ Exp Med2001194451952711514607
  • HuangWNaLFidelPLSchwarzenbergerPRequirement of interleukin-17A for systemic anti-Candida albicans host defense in miceJ Infect Dis2004190362463115243941
  • OuyangWKollsJKZhengYThe biological functions of T helper 17 cell effector cytokines in inflammationImmunity200828445446718400188
  • MilnerJDBrenchleyJMLaurenceAImpaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndromeNature2008452718877377618337720
  • MaCSChewGYSimpsonNDeficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3J Exp Med200820571551155718591410
  • BurkettPRMeyer zu HorsteGKuchrooVKPouring fuel on the fire: Th17 cells, the environment, and autoimmunityJ Clin Invest201512562211221925961452
  • WuHJIvanovIIDarceJGut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cellsImmunity201032681582720620945
  • KirkhamBWKavanaughAReichKInterleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritisImmunology2014141213314223819583
  • FossiezFDjossouOChomaratPT cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokinesJ Exp Med19961836259326038676080
  • KotakeSUdagawaNTakahashiNIL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJ Clin Invest199910391345135210225978
  • ChabaudMMiossecPThe combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo modelArthritis Rheum20014461293130311407688
  • LeGrandAFermorBFinkCInterleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisciArthritis Rheum20014492078208311592370
  • KoshyPJHendersonNLoganCLifePFCawstonTERowanADInterleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokinesAnn Rheum Dis200261870471312117676
  • Van BezooijenRLVan Der Wee-PalsLPapapoulosSELöwikCWInterleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitroAnn Rheum Dis2002611087087612228154
  • ChabaudMDurandJMBuchsNHuman interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synoviumArthritis Rheum199942596397010323452
  • ZiolkowskaMKocALuszczykiewiczGHigh levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanismJ Immunol200016452832283810679127
  • GullickNJAbozaidHSJayarajDMEnhanced and persistent levels of interleukin (IL)-17+ CD4+ T cells and serum IL-17 in patients with early inflammatory arthritisClin Exp Immunol2013174229230123815507
  • ShenHXiaLLuJXiaoWInfliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritisJ Investig Med2010587905908
  • ChenDYChenYMChenHHHsiehCWLinCCLanJLIncreasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapyArthritis Res Ther2011134R12621801431
  • AlzabinSAbrahamSMTaherTEIncomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathwayAnn Rheum Dis201271101741174822550316
  • HullDNWilliamsROPathanEAlzabinSAbrahamSTaylorPCAnti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritisClin Exp Immunol2015181340140625766640
  • MenonBGullickNJWalterGJInterleukin-17+ CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progressionArthritis Rheumatol20146651272128124470327
  • Van BaarsenLGMLebreMCvan der CoelenDSnoekBCGerlagDMTakPPIL-17 levels in synovium of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis: target validation in various forms of arthritisAnn Rheum Dis201170A79
  • HüffmeierUUebeSEkiciABCommon variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasisNat Genet2010421199699920953186
  • RuedaBOrozcoGRayaEThe IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitisAnn Rheum Dis200867101451145418199597
  • NakaeSNambuASudoKIwakuraYSuppression of immune induction of collagen-induced arthritis in IL-17-deficient miceJ Immunol2003171116173617714634133
  • NakaeSSaijoSHoraiRSudoKMoriSIwakuraYIL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonistProc Natl Acad Sci U S A2003100105986599012721360
  • KoendersMIKollsJKOppers-WalgreenBInterleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritisArthritis Rheum200552103239324716200598
  • LubbertsEKoendersMIOppers-WalgreenBTreatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosionArthritis Rheum200450265065914872510
  • KoendersMIDevesaIMarijnissenRJInterleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient miceArthritis Rheum200858113461347018975337
  • KoendersMILubbertsEOppers-WalgreenBBlocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1Am J Pathol2005167114114915972960
  • KoendersMIMarijnissenRJDevesaITumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritisArthritis Rheum20116382329233921520013
  • Plater-ZyberkCJoostenLAHelsenMMKoendersMIBaeuerlePAvan den BergWBCombined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse modelAnn Rheum Dis200968572172818495731
  • van NieuwenhuijzeAEvan de LooFAWalgreenBComplementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritisArthritis Res Ther20151716326081345
  • RuutuMThomasGSteckRβ-glucan triggers spondyloarthritis and Crohn’s disease-like ileitis in SKG miceArthritis Rheum20126472211222222328069
  • BenhamHRehaumeLMHasnainSZInterleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of spondyloarthritis pathology in SKG miceArthritis Rheumatol20146671755176724664521
  • LangleyRGElewskiBELebwohlMERASURE Study GroupFIXTURE Study GroupSecukinumab in plaque psoriasis – results of two phase 3 trialsN Engl J Med2014371432633825007392
  • GenoveseMCDurezPRichardsHBEfficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyAnn Rheum Dis201372686386922730366
  • MeasePJMcInnesIBKirkhamBFUTURE 1 Study GroupSecukinumab inhibition of interleukin-17A in patients with psoriatic arthritisN Engl J Med2015373141329133926422723
  • McInnesIBMeasePJKirkhamBFUTURE 2 Study GroupSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet201538699991137114626135703
  • BaetenDLBraunJBaraliakosXSecukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosingArthritis Rheumatol201466S10S360
  • BraunJDeodharAASieperJSecukinumab significantly improves signs and symptoms of active ankylosing spondylitis: 52-week results from a randomized, double-blind, placebo-controlled phase 3 trial with subcutaneous loading and maintenance dosing [abstract]Arthritis Rheumatol201567suppl 10
  • BurmesterGRDurezPShestakovaGAssociation of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritisRheumatology (Oxford)2016551495526268815
  • LebwohlMStroberBMenterAPhase 3 studies comparing brodalumab with ustekinumab in psoriasisN Engl J Med2015373141318132826422722
  • AmgenAmgen to Terminate Participation in Co-development and Commercialization of Brodalumab [press release]Thousand Oaks, CAPRNewswire2015522 Available from: http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=2052862
  • DaneshMJKimballABBrodalumab and suicidal ideation in the context of a recent economic crisis in the United StatesJ Am Acad Dermatol201674119019226702804
  • HueberWPatelDDDryjaTEffects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitisSci Transl Med201025252ra72
  • PappKALangleyRGSigurgeirssonBEfficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyBr J Dermatol2013168241242123106107
  • BlauveltAPrinzJCGottliebABFEATURE Study GroupSecukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)Br J Dermatol2015172248449325132411
  • GenoveseMCDurezPRichardsHBOne-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled studyJ Rheumatol201441341442124429175
  • KoendersMIMarijnissenRJJoostenLAT cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralizationArthritis Rheum20126461762177022213107
  • Novartis PharmaceuticalsEfficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents (REASSURE) Available from: https://clinicaltrials.gov/ct2/show/NCT01377012
  • Novartis PharmaceuticalsSafety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA. (REASSURE-E) Available from: https://clinicaltrials.gov/ct2/show/NCT01901900
  • McInnesIBSieperJBraunJEfficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trialAnn Rheum Dis201473234935623361084
  • NovartisNovartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis Available from: https://www.novartis.com/news/media-releases/novartis-receives-two-landmark-european-approvals-cosentyx-treat-patients
  • BaetenDBaraliakosXBraunJAnti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trialLancet201338299061705171324035250
  • BaraliakosXBorahBBraunJLong-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational studyAnn Rheum Dis201675240841226248638
  • BaraliakosXDeodharAABraunJEffect of interleukin-17A inhibition on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of a phase 3 study with secukinumab [abstract]Arthritis Rheumatol201567suppl 10
  • BaetenDSieperJBraunJMEASURE 1 Study GroupMEASURE 2 Study GroupSecukinumab, an interleukin-17A Inhibitor, in ankylosing spondylitisN Engl J Med2015373262534254826699169
  • HueberWSandsBELewitzkySSecukinumab in Crohn’s Disease Study GroupSecukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trialGut201261121693170022595313
  • TarganSRFeaganBGVermeireSA randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn’s diseaseGastroenterology2012143E26
  • O’ConnorWJrZenewiczLAFlavellRAThe dual nature of T(H)17 cells: shifting the focus to functionNat Immunol201011647147620485275
  • DinarelloCASimonAvan der MeerJWTreating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNat Rev Drug Discov201211863365222850787
  • BraunJvan den BergRBaraliakosX2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisAnn Rheum Dis201170689690421540199
  • SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
  • SmolenJSBraunJDougadosMTreating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task forceAnn Rheum Dis201473161623749611
  • GossecLSmolenJSRamiroSEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateAnn Rheum Dis201675349951026644232